ArticleArthritis care & research2015
Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population-based retrospective cohort study.
Article in Arthritis care & research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 60 citations in OpenAlex.
- Burden of incident cardiovascular events in giant cell arteritis using data from a nationwide French cohort.Scientific reports · 2026Article
- Risk factors for acute coronary syndrome in patients with giant cell arteritis: a scoping review.Therapeutic advances in musculoskeletal disease · 2026Article
- Association of SSRI and SNRI use with incidence of cardiovascular events in veterans with giant cell arteritis and polymyalgia rheumatica.Frontiers in immunology · 2025Article
- Antiplatelet therapy to prevent ischemic events in giant cell arteritis: protocol for a systematic review and meta-analysis.Systematic reviews · 2024Article
- An Updated Review of Cardiovascular Events in Giant Cell Arteritis.Journal of clinical medicine · 2022Review
- Cardiovascular lesions in giant cell arteritis.Reumatologia · 2022Review
- Intima-media thickness cut-off values depicting "halo sign" and potential confounder analysis for the best diagnosis of large vessel giant cell arteritis by ultrasonography.Frontiers in medicine · 2022Article
- Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis.Scientific reports · 2021Article
- Familial aggregation of longevity in giant cell arteritis and polymyalgia rheumatica.Rheumatology international · 2020Article
- Article
- Vascular calcification in patients with large-vessel vasculitis compared to patients with hyperlipidemia.Seminars in arthritis and rheumatism · 2019Article
- Article
- Venous Thromboembolism and Cerebrovascular Events in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study.PloS one · 2016Article
- Lower body mass index is associated with a higher risk of giant cell arteritis: a systematic review and meta-analysis.Annals of translational medicine · 2015Article
- Hospitalization rates and utilization among patients with giant cell arteritis: A population-based study from 1987 to 2012.Seminars in arthritis and rheumatism · 2015Article
- Thrombosis in vasculitis: from pathogenesis to treatment.Thrombosis journal · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo assess the occurrence of acute coronary syndrome (ACS) in patients with giant cell arteritis (GCA) compared to subjects without GCA.
methodsWe retrospectively reviewed a population-based incidence cohort of Olmsted County, Minnesota residents with GCA diagnosed in 1950-2009. We compared this cohort with a cohort of patients without GCA of similar age, sex, and calendar year from the same population.
resultsThe study included 245 patients with GCA and 245 non-GCA subjects. The mean ± SD Framingham cardiovascular risk score was 30% ± 19% in GCA patients and 34% ± 23% in non-GCA subjects (P = 0.096) at the incidence/index date. Diabetes mellitus was significantly less common in GCA patients than non-GCA subjects at the index date. The mean high-density lipoprotein was higher and triglycerides were lower, with fewer patients taking lipid-lowering medications in the GCA cohort compared to the non-GCA cohort at the index date. During followup, no difference between the 2 cohorts was noted in the overall rate of ACS events (hazard ratio 0.74, 95% confidence interval 0.44-1.26). Overall thrombosis in myocardial infarction scores were similar in both cohorts. Revascularization procedures were done less frequently in GCA than in non-GCA subjects (19% versus 50%; P = 0.015). Post-ACS hospital length of stays and complications were similar in both cohorts.
conclusionMultiple cardiovascular risk factors are less atherogenic at incidence of GCA. There is no overall increased risk of ACS in patients with GCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.